EP3790557A4 - Compositions and methods for improving strand biased - Google Patents

Compositions and methods for improving strand biased Download PDF

Info

Publication number
EP3790557A4
EP3790557A4 EP19799574.9A EP19799574A EP3790557A4 EP 3790557 A4 EP3790557 A4 EP 3790557A4 EP 19799574 A EP19799574 A EP 19799574A EP 3790557 A4 EP3790557 A4 EP 3790557A4
Authority
EP
European Patent Office
Prior art keywords
compositions
methods
improving strand
biased
strand biased
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19799574.9A
Other languages
German (de)
French (fr)
Other versions
EP3790557A2 (en
Inventor
Muthiah Manoharan
Rubina G. Parmar
Pawan Kumar
Masaaki AKABANE-NAKATA
Shigeo Matsuda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alnylam Pharmaceuticals Inc
Original Assignee
Alnylam Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alnylam Pharmaceuticals Inc filed Critical Alnylam Pharmaceuticals Inc
Publication of EP3790557A2 publication Critical patent/EP3790557A2/en
Publication of EP3790557A4 publication Critical patent/EP3790557A4/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3233—Morpholino-type ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/332—Abasic residue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/343—Spatial arrangement of the modifications having patterns, e.g. ==--==--==--
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance
EP19799574.9A 2018-05-07 2019-05-07 Compositions and methods for improving strand biased Pending EP3790557A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862667972P 2018-05-07 2018-05-07
US201962811870P 2019-02-28 2019-02-28
PCT/US2019/031083 WO2019217397A2 (en) 2018-05-07 2019-05-07 Compositions and methods for improving strand biased

Publications (2)

Publication Number Publication Date
EP3790557A2 EP3790557A2 (en) 2021-03-17
EP3790557A4 true EP3790557A4 (en) 2022-03-02

Family

ID=68467615

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19799574.9A Pending EP3790557A4 (en) 2018-05-07 2019-05-07 Compositions and methods for improving strand biased

Country Status (3)

Country Link
US (1) US20210238594A1 (en)
EP (1) EP3790557A4 (en)
WO (1) WO2019217397A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022011012A (en) 2020-03-06 2022-10-07 Aligos Therapeutics Inc Modified short interfering nucleic acid (sina) molecules and uses thereof.
CA3179931A1 (en) * 2020-04-10 2021-10-14 Aligos Therapeutics, Inc. Short interfering nucleic acid (sina) molecules and uses thereof for coronavirus diseases
WO2023039005A2 (en) * 2021-09-08 2023-03-16 Aligos Therapeutics, Inc. Modified short interfering nucleic acid (sina) molecules and uses thereof
TW202400787A (en) 2022-03-16 2024-01-01 美商安彼瑞可股份有限公司 Galnac compositions for improving sirna bioavailability

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170275626A1 (en) * 2014-08-20 2017-09-28 Alnylam Pharmaceuticals, Inc. Modified double-stranded rna agents
WO2021072395A1 (en) * 2019-10-11 2021-04-15 Alnylam Pharmaceuticals, Inc. Modified oligonucleotides

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8232383B2 (en) * 2002-02-20 2012-07-31 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
AU2005238490B2 (en) * 2004-04-22 2010-11-18 Tobira Therapeutics, Inc. Improved modulators of coagulation factors
JP5646997B2 (en) * 2007-10-03 2014-12-24 クォーク ファーマシューティカルズ インコーポレーティッドＱｕａｒｋ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Novel siRNA structure
US20140170191A1 (en) * 2008-10-23 2014-06-19 Hemispher Biopharma, Inc. Novel double-stranded ribonucleic acids with rugged physico-chemical structure and highly specific biologic activity
SG10201913786SA (en) * 2016-11-23 2020-03-30 Alnylam Pharmaceuticals Inc Modified rna agents with reduced off-target effect

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170275626A1 (en) * 2014-08-20 2017-09-28 Alnylam Pharmaceuticals, Inc. Modified double-stranded rna agents
WO2021072395A1 (en) * 2019-10-11 2021-04-15 Alnylam Pharmaceuticals, Inc. Modified oligonucleotides

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
JANAS MAJA M. ET AL: "Supplementary Information Selection of GalNAc-conjugated siRNAs with limited off-target-driven rat hepatotoxicity", NATURE COMMUNICATIONS, 19 February 2018 (2018-02-19), XP055882412, Retrieved from the Internet <URL:https://static-content.springer.com/esm/art%3A10.1038%2Fs41467-018-02989-4/MediaObjects/41467_2018_2989_MOESM1_ESM.docx> [retrieved on 20220121] *
KUMAR PAWAN ET AL: "5'-Morpholino modification of the sense strand of an siRNA makes it a more effective passenger", CHEMICAL COMMUNICATIONS, vol. 55, no. 35, 25 April 2019 (2019-04-25), UK, pages 5139 - 5142, XP055826733, ISSN: 1359-7345, DOI: 10.1039/C9CC00977A *
MAJA M. JANAS ET AL: "Selection of GalNAc-conjugated siRNAs with limited off-target-driven rat hepatotoxicity", NATURE COMMUNICATIONS, vol. 9, no. 1, 19 February 2018 (2018-02-19), pages 1 - 10, XP055488485, DOI: 10.1038/s41467-018-02989-4 *
P. R. CLARK ET AL: "Knockdown of TNFR1 by the sense strand of an ICAM-1 siRNA: dissection of an off-target effect", NUCLEIC ACIDS RESEARCH, vol. 36, no. 4, 1 January 2007 (2007-01-01), pages 1081 - 1097, XP055000172, ISSN: 0305-1048, DOI: 10.1093/nar/gkm630 *
PARMAR RUBINA ET AL: "Supporting Information 5'-(E)-Vinylphosphonate: A Stable Phosphate Mimic Can Improve the RNAi Activity of siRNA-GalNAc Conjugates", 28 April 2016 (2016-04-28), XP055882308, Retrieved from the Internet <URL:https://chemistry-europe.onlinelibrary.wiley.com/action/downloadSupplement?doi=10.1002/cbic.201600130&file=cbic201600130-sup-0001-misc_information.pdf> [retrieved on 20220121] *
REKA A. HARASZTI ET AL: "5'-Vinylphosphonate improves tissue accumulation and efficacy of conjugated siRNAs in vivo", NUCLEIC ACIDS RESEARCH, vol. 45, no. 13, 7 June 2017 (2017-06-07), GB, pages 7581 - 7592, XP055599779, ISSN: 0305-1048, DOI: 10.1093/nar/gkx507 *
RUBINA PARMAR ET AL: "5'-( E )-Vinylphosphonate: A Stable Phosphate Mimic Can Improve the RNAi Activity of siRNA-GalNAc Conjugates", CHEMBIOCHEM, vol. 17, no. 11, 28 April 2016 (2016-04-28), pages 985 - 989, XP055448304, ISSN: 1439-4227, DOI: 10.1002/cbic.201600130 *

Also Published As

Publication number Publication date
US20210238594A1 (en) 2021-08-05
WO2019217397A2 (en) 2019-11-14
EP3790557A2 (en) 2021-03-17
WO2019217397A3 (en) 2020-07-23

Similar Documents

Publication Publication Date Title
EP3823673A4 (en) Anti-cd112r compositions and methods
EP3765608A4 (en) Gene-regulating compositions and methods for improved immunotherapy
EP3471745A4 (en) Methods and compositions for reducing oxidative stress
EP3765094A4 (en) Gene-regulating compositions and methods for improved immunotherapy
EP3600325A4 (en) Novel compositions and methods
IL285302A (en) Compounds, compositions and methods
EP3765092A4 (en) Gene-regulating compositions and methods for improved immunotherapy
EP3704227A4 (en) Composition and method
EP3852608A4 (en) Compositions and methods for glaucoma
EP3790557A4 (en) Compositions and methods for improving strand biased
EP3844500A4 (en) Rp182 compositions and methods
EP3931336A4 (en) Compositions and methods for treating laminopathies
EP3706558A4 (en) Compositions and methods for aquaculturing
EP3843729A4 (en) Novel compositions and methods
IL288024A (en) Methods and compositions for preventing type
EP3897615A4 (en) Cannabis compositions and methods
IL286587A (en) D-metyrosine compositions and methods for preparing same
IL287120A (en) Compounds, compositions and methods
EP3818245A4 (en) Cement compositions and methods
EP3595640A4 (en) Compositions and methods for treating multiple sclerosis
IL290325A (en) Biopharmacuetical compositions and related methods
EP3917320A4 (en) Bacterialcidal methods and compositions
EP3856184A4 (en) Compositions and methods for inhibiting acss2
GB2579687B (en) Composition and method
GB201914777D0 (en) Composition and method

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20201203

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0031713000

Ipc: C07H0021020000

A4 Supplementary search report drawn up and despatched

Effective date: 20220131

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/11 20060101ALI20220126BHEP

Ipc: C12N 15/09 20060101ALI20220126BHEP

Ipc: C12N 15/113 20100101ALI20220126BHEP

Ipc: C07H 21/02 20060101AFI20220126BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ALNYLAM PHARMACEUTICALS INC.

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230520